Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.